Abbvie Inc.

Georgetown University

Debra Chao

Archana Thakur

Chung-Ming Hsieh

Jieyi Wang

Edward B Reilly

Mark Anderson

Qian Zhang

Charles W Hutchins

Andrew J Souers

J Yun Tso

Milan Bruncko

Kenton L Longenecker

Lorenzo Benatuil

Andrew S Judd

Anton Wellstein

Andrew C Phillips

Enrico L Digiammarino

Kamel Izeradjene

Russell A Judge

David A Egan

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-B7-H3 antibodies and antibody drug conjugates

The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Prolactin receptor binding proteins and uses thereof

The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.

Anti-pleiotrophin antibodies and methods of use thereof

Growing community of inventors

Fremont, CA, United States of America

Debra Chao